MELATONIN

Hypersomnia

Duke UniversitySmall moleculePhase 2Active

B

57/ 100

Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence: 42/ 100
Competitive Position: 95/ 100

Competitive context

3 Active assets in the Hypersomnia cohort.

Asset / Sponsor	Phase	Rating
Solriamfetol Duke University	Phase 2	BB
CAFFEINE Ron Postuma	Phase 2/3	B
Modafinil Duke University	Phase 2	B
Valiloxybate XWPharma	Phase 2	CCC
.GAMMA.-HYDROXYBUTYRATE SODIUM SALT Brigham and Women's Hospital	Early Phase 1	C
Gate-101 Syndeio Biosciences, Inc	Phase 1	NR

Same molecule, other indications

MELATONIN is also rated in:

traumatic brain injuryDormant

BBB

Indicative ·

74 / 100

bipolar disorderDormant

BBB

Indicative ·

72 / 100

circadian rhythm sleep disorderDormant

BB

Indicative ·

69 / 100

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.